Literature DB >> 24152953

Histological advantages of the tumor graft: a murine model involving transplantation of human pancreatic cancer tissue fragments.

Yoshimasa Akashi1, Tatsuya Oda, Yusuke Ohara, Ryoichi Miyamoto, Shinji Hashimoto, Tsuyoshi Enomoto, Keiichi Yamada, Akihiko Kobayashi, Kiyoshi Fukunaga, Nobuhiro Ohkochi.   

Abstract

OBJECTIVES: Experimental data based on cell line-derived xenograft models (cell xenograft) seldom reproduce the clinical situation, and therefore we demonstrated here the superiority of a murine model involving transplantation of human pancreatic cancer tissue fragments (tumor graft), focusing on the histological features and drug delivery characteristics.
METHODS: Tumor pieces from 10 pancreatic cancer patients were transplanted into SCID (severe combined immunodeficient) mice. Histological characteristics of tumor grafts, including morphology, desmoplastic reaction, and vascularization, were compared with those of cell xenografts. Drug delivery was evaluated by quantifying the concentrations of injected drug, and the results were compared with its histological features.
RESULTS: Eight of the 10 transplanted tumors successfully engrafted. Histological comparisons between tumor grafts and cell xenografts revealed the following: the amount of stroma was more (22.9% ± 11.8% vs 10.8% ± 5.4%; P < 0.05), vessel-cancer cell distance was longer (35.3 ± 39.0 vs 3.9 ± 3.1 μm; P < 0.001), and microvessel density was lower (6.8 ± 1.9 vs 10.8 ± 2.1 vessels/0.4 mm(2); P < 0.05) in tumor grafts. Drug concentrations in tumor grafts were lower than those in cell xenografts (3.3 ± 1.2 vs 6.0±0.2 μg/mL; P = 0.003), and the differences were correlated with the histological differences.
CONCLUSIONS: Pancreatic tumor grafts better reproduce the histological nature of clinical cancer and thus provide a more realistic model that is applicable for pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24152953     DOI: 10.1097/MPA.0b013e318296f866

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer.

Authors:  Ryoichi Miyamoto; Tatsuya Oda; Shinji Hashimoto; Tomohiro Kurokawa; Yuki Inagaki; Osamu Shimomura; Yusuke Ohara; Keiichi Yamada; Yoshimasa Akashi; Tsuyoshi Enomoto; Mikio Kishimoto; Hideto Yanagihara; Eiji Kita; Nobuhiro Ohkohchi
Journal:  Cancer Sci       Date:  2016-03-04       Impact factor: 6.716

2.  Translational pancreatic cancer research: A comparative study on patient-derived xenograft models.

Authors:  Mercedes Rubio-Manzanares Dorado; Luis Miguel Marín Gómez; Daniel Aparicio Sánchez; Sheila Pereira Arenas; Juan Manuel Praena-Fernández; Juan Jose Borrero Martín; Francisco Farfán López; Miguel Ángel Gómez Bravo; Jordi Muntané Relat; Javier Padillo Ruiz
Journal:  World J Gastroenterol       Date:  2018-02-21       Impact factor: 5.742

3.  Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model.

Authors:  Yoshihiro Miyazaki; Tatsuya Oda; Yuki Inagaki; Hiroko Kushige; Yutaka Saito; Nobuhito Mori; Yuzo Takayama; Yutaro Kumagai; Toutai Mitsuyama; Yasuyuki S Kida
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

Review 4.  Pancreatic cancer stroma: an update on therapeutic targeting strategies.

Authors:  Abdel N Hosein; Rolf A Brekken; Anirban Maitra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-11       Impact factor: 73.082

5.  Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.

Authors:  Y Akashi; T Oda; Y Ohara; R Miyamoto; T Kurokawa; S Hashimoto; T Enomoto; K Yamada; M Satake; N Ohkohchi
Journal:  Br J Cancer       Date:  2014-02-20       Impact factor: 7.640

6.  Adipose-derived mesenchymal stem cells differentiate into pancreatic cancer-associated fibroblasts in vitro.

Authors:  Yoshihiro Miyazaki; Tatsuya Oda; Nobuhito Mori; Yasuyuki S Kida
Journal:  FEBS Open Bio       Date:  2020-10-09       Impact factor: 2.792

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.